BRIGHT MINDS BIOSCIENCES INC.
DRUGDrugs in Pipeline
6
Phase 3 Programs
3
Upcoming Catalysts
3
Next Catalyst
Aug 13, 2026
8dMarket Overview
Stock performance and key metrics
3 upcoming, 1 past
DRUG Earnings Report
EPS Est: $-1.39 | FQ end 2026-06
2 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
Semaglutide
Type 2 Diabetes (T2DM)
Drug: : 10 mg BGM0504 Administered SC
Type 2 Diabetes Mellitus (T2DM)
Drug: 5 mg BGM0504 Administered SC
Type 2 Diabetes Mellitus (T2DM)
BMB-101
Absence Epilepsy
BGM0504
Overweight or Obesity
BGM0504 Administered SC
Type 2 Diabetes
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Semaglutide | Phase 3 | Type 2 Diabetes (T2DM) | - | - |
Drug: : 10 mg BGM0504 Administered SC | Phase 3 | Type 2 Diabetes Mellitus (T2DM) | - | - |
Drug: 5 mg BGM0504 Administered SC | Phase 3 | Type 2 Diabetes Mellitus (T2DM) | - | - |
BMB-101 | Phase 2 | Absence Epilepsy | - | - |
BGM0504 | Phase 2 | Overweight or Obesity | - | - |
BGM0504 Administered SC | Phase 2 | Type 2 Diabetes | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in BRIGHT MINDS BIOSCIENCES INC.'s drug pipeline?→
CatalystAlert tracks 6 drug candidates in BRIGHT MINDS BIOSCIENCES INC.'s (DRUG) pipeline across Phase 3, Phase 2. Its lead program is Semaglutide (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is BRIGHT MINDS BIOSCIENCES INC.'s next FDA catalyst?→
BRIGHT MINDS BIOSCIENCES INC.'s (DRUG) next tracked catalyst is a Phase 3 expected July 31, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track DRUG biotech catalysts?→
Add DRUG to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow BRIGHT MINDS BIOSCIENCES INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.